Richard Glynne joined Inception Therapeutics as Chief Scientific Officer (CSO) in 2018 and has helped form several biotech companies in this position, including Belharra Therapeutics. Richard served as interim CSO of Belharra while in seed stage, joined the board in 2023, and assumed the interim CEO role in 2025. Richard joined Inception after leading search and evaluation for immune oncology, immunology and digital therapeutics in the business development group at Novartis. Prior to the BD role, Richard served as an Executive Director, leading a research group at the Genomics Institute of the Novartis Research Foundation, that focused on infectious disease and immunology and contributed to multiple pre-clinical and clinical development programs. Richard trained in immunology and genetics during his PhD (ICRF, London) and post-doc (HHMI, Stanford), after which he held leadership positions in Eos Biotechnology and Phenomix Corporation, before joining Novartis in 2004.